DXCM

DexCom (DXCM) reported strong Q2 2026 results with gross margin expanding to 64.1% and operating margin at 25.1%, driven by manufacturing efficiencies and G7 15-day product transition. However, near-term profitability could face pressure from Ireland factory ramp-up costs, forex headwinds, and higher oil-linked input costs. The company maintains a Zacks Rank #3 (Hold) rating with shares up 29.4% year-to-date.

Dexcom released its 2026 State of Type 2 Report highlighting significant gaps in CGM awareness and reimbursement access, with 55% of Type 2 diabetes patients having limited knowledge of the technology. However, the report reveals substantial growth opportunities as 58% of Type 2 patients on GLP-1 medicines use CGM, and a majority are open to CGM when recommended alongside GLP-1 therapy. Competitors Abbott Laboratories and MiniMed are also expanding their CGM portfolios with innovative features and sensor technologies.

ViCentra announced real-world data from 3,918 adults showing its Kaleido insulin patch pump system achieved 72.2% median time in range with minimal hypoglycemia (0.21% time below 54 mg/dL) and low glycemic variability (28.7% coefficient of variation) across Germany, the Netherlands, and France. The system, integrated with Diabeloop's DBLG1 algorithm and Dexcom G6, demonstrated strong clinical performance in routine use with high user engagement.